Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Maintains Overweight on Ambarella, Lowers Price Target to $100

Keybanc analyst John Vinh maintains Ambarella (NASDAQ:AMBA) with a Overweight and lowers the price target from $120 to $100.

byBenzinga Newsdesk

August 31, 2022

1 minute read

Keybanc analyst John Vinh maintains Ambarella (NASDAQ:AMBA) with a Overweight and lowers the price target from $120 to $100.

FDA
News

Paratek Pharmaceuticals Granted Orphan Drug Designation For Treatment Of Infections Caused By Nontuberculous Mycobacteria

By Benzinga Newsdesk

Today, 11:29 PM

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=741020

PRTK

Bernstein Upgrades Stryker to Outperform, Raises Price Target to $295

By Benzinga Newsdesk

Today, 11:29 PM

Bernstein analyst Lee Hambright upgrades Stryker (NYSE:SYK) from Market Perform to Outperform and raises the price target from $288 to $295.

SYK

Zhihu Clocks 144% Revenue Growth In Q2, Issues Solid Q3 Outlook

By Anusuya Lahiri

Today, 11:29 PM

Online content community Zhihu Inc (NYSE:ZH) reported second-quarter FY21 revenue growth of 144.2% year-on-year to $98.9 million, beating the analyst consensus of…

MSFT

Analyst Ratings

Analyst Ratings For Wabash National

By Benzinga Insights

Today, 11:29 PM

Analysts have provided the following ratings for Wabash National (NYSE:WNC) within the last quarter:

WNC

Keybanc Maintains Overweight on Ambarella, Lowers Price Target to $100

Related Posts

Paratek Pharmaceuticals Granted Orphan Drug Designation For Treatment Of Infections Caused By Nontuberculous Mycobacteria

Bernstein Upgrades Stryker to Outperform, Raises Price Target to $295

Zhihu Clocks 144% Revenue Growth In Q2, Issues Solid Q3 Outlook

Analyst Ratings For Wabash National